Trophos pursues olesoxime into MS despite late-stage ALS failure
This article was originally published in Scrip
Executive Summary
Despite crashing in late-stage trials in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), French biotech Trophos is hoping its mitochondrial pore modulator, olesoxime, will fare better in the indication of multiple sclerosis (MS).